Furthermore, in a recent randomized, double-blind, placebo-controlled Phase IIa study, the effects of a selective small molecule SIRT1 activator in 40 patients with moderate-to-severe psoriasis were investigated [41]. This evidence concerns the gene SIRT1 and psoriasis.